The Value Of Tissue Retinoblastoma Gene (RB1) Expression Levels In Colorectal Cancer And Inflammatory Bowel Disease

Abstract

Background: Colorectal cancer (crc) is one of the most important and prevalent digestive tract malignant tumors with poor prognosis. Cancer biomarkers play a crucial role in outlining the prognosis of a disease independently of any treatment (known as prognostic biomarkers) or in predicting how a cancer will respond to a specific treatment, which helps anticipate treatment outcomes (referred to as predictive biomarkers). Retinoblastoma (Rb1) represents a critical tumor suppressor gene in different tumor types, governing diverse cellular processes implicated in cancer biology Subjects and Methods: 49 paired colorectal tumors and non-tumor marginal tissues, as well as 21 tissue biopsies taken from patients with inflammatory bowel disease. Total RNA was extracted from the samples and cDNAs were synthesized. Their expression was quantified by qRT-PCR. Results: We observed significant upregulation of RB1 in the colorectal tumors compared with non-tumor as well as inflammatory tissues sample from IBD patients. RB1 expression was significantly elevated with higher tumor marker (CA19-9 and CA125). ROC curve analysis showed that RB1 expression levels could discriminate tumor from non-tumor and IBD. Conclusion: RB1 expression levels could discriminate colorectal tumors from non-tumor tissues, as well as from IBD, highlighting their potential as biomarkers for colorectal cancer development